In a report released today, Joseph Stringer from Needham maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $55.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Joseph Stringer has given his Buy rating due to a combination of factors surrounding Ionis Pharmaceuticals’ recent developments. The approval of Dawnzera (donidalorsen) by the FDA for hereditary angioedema (HAE) prophylaxis marks a significant milestone for the company. This approval was based on positive results from the Phase 3 OASIS-HAE study, indicating strong clinical efficacy.
Additionally, the pricing strategy for Dawnzera aligns with competitors in the market, positioning it competitively against other treatments like Andembry and Takhzyro. Despite the crowded U.S. HAE prophylaxis market, Ionis has a strategic partnership with Otsuka for marketing outside the U.S., which could enhance its revenue potential. Stringer projects substantial revenue from Dawnzera in the coming years, contributing to his optimistic outlook on the stock.
In another report released on August 19, Jefferies also reiterated a Buy rating on the stock with a $83.00 price target.